<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Gallet Q</submitter><funding>Medical Research Council</funding><pagination>1114-1120</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8938511</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>47(5)</volume><pubmed_abstract>Recent evidence suggests an association between benzodiazepines (BZDs) use and lower brain amyloid load, a hallmark of AD pathophysiology. Other AD-related markers include hippocampal atrophy, but the effect of BZDs on hippocampal volume remains unclear. We aimed at 1) replicating findings on BZDs use and brain amyloid load and 2) investigating associations between BZDs use and hippocampal volume, in the MEMENTO clinical cohort of nondemented older adults with isolated memory complaint or light cognitive impairment at baseline. Total Standardized Uptake Value Ratio (SUVR) of brain amyloid load and hippocampal volume (HV) were obtained, respectively, from &lt;sup>18&lt;/sup>F Florbetapir positron emission tomography (PET) and magnetic resonance imaging (MRI), and compared between BZD chronic user</pubmed_abstract><journal>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</journal><pubmed_title>Benzodiazepine use and neuroimaging markers of Alzheimer's disease in nondemented older individuals: an MRI and 18F Florbetapir PET study in the MEMENTO cohort.</pubmed_title><pmcid>PMC8938511</pmcid><funding_grant_id>MR/L023784/2</funding_grant_id><funding_grant_id>MR/T033371/1</funding_grant_id><pubmed_authors>Gallet Q</pubmed_authors><pubmed_authors>MEMENTO study group</pubmed_authors><pubmed_authors>Chupin M</pubmed_authors><pubmed_authors>Cottier JP</pubmed_authors><pubmed_authors>Habert MO</pubmed_authors><pubmed_authors>Barantin L</pubmed_authors><pubmed_authors>Gohier B</pubmed_authors><pubmed_authors>Bulteau S</pubmed_authors><pubmed_authors>Belzung C</pubmed_authors><pubmed_authors>Locatelli M</pubmed_authors><pubmed_authors>Arlicot N</pubmed_authors><pubmed_authors>Desmidt T</pubmed_authors><pubmed_authors>Ribeiro MJ</pubmed_authors><pubmed_authors>Andersson F</pubmed_authors><pubmed_authors>Delrieu J</pubmed_authors><pubmed_authors>Surget A</pubmed_authors><pubmed_authors>El-Hage W</pubmed_authors><pubmed_authors>Robert G</pubmed_authors><pubmed_authors>Gissot V</pubmed_authors><pubmed_authors>David R</pubmed_authors><pubmed_authors>Lebouvier T</pubmed_authors><pubmed_authors>Bouteloup V</pubmed_authors><pubmed_authors>Camus V</pubmed_authors><pubmed_authors>Balageas AC</pubmed_authors></additional><is_claimable>false</is_claimable><name>Benzodiazepine use and neuroimaging markers of Alzheimer's disease in nondemented older individuals: an MRI and 18F Florbetapir PET study in the MEMENTO cohort.</name><description>Recent evidence suggests an association between benzodiazepines (BZDs) use and lower brain amyloid load, a hallmark of AD pathophysiology. Other AD-related markers include hippocampal atrophy, but the effect of BZDs on hippocampal volume remains unclear. We aimed at 1) replicating findings on BZDs use and brain amyloid load and 2) investigating associations between BZDs use and hippocampal volume, in the MEMENTO clinical cohort of nondemented older adults with isolated memory complaint or light cognitive impairment at baseline. Total Standardized Uptake Value Ratio (SUVR) of brain amyloid load and hippocampal volume (HV) were obtained, respectively, from &lt;sup>18&lt;/sup>F Florbetapir positron emission tomography (PET) and magnetic resonance imaging (MRI), and compared between BZD chronic user</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Apr</publication><modification>2026-06-19T04:53:07.862Z</modification><creation>2025-04-06T00:05:38.282Z</creation></dates><accession>S-EPMC8938511</accession><cross_references><pubmed>34893757</pubmed><doi>10.1038/s41386-021-01246-5</doi></cross_references></HashMap>